Convatec Group Plc, headquartered in Great Britain, is a leading global medical technology company specialising in advanced wound care, ostomy care, continence and critical care, and infusion devices. Founded in 1978, Convatec has established itself as a pioneer in the healthcare industry, focusing on innovative solutions that enhance patient outcomes. With a strong presence in Europe, North America, and Asia-Pacific, Convatec offers a diverse range of products, including hydrocolloid dressings and advanced ostomy appliances, known for their quality and effectiveness. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted partner in healthcare. Convatec's dedication to improving the lives of patients and healthcare professionals alike underscores its reputation as a market leader in medical technology.
How does Convatec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Convatec's score of 72 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Convatec reported total carbon emissions of approximately 138,230,000 kg CO2e globally, with significant contributions from Scope 1 emissions at about 12,360,000 kg CO2e, Scope 2 emissions at around 1,463,000 kg CO2e, and a substantial Scope 3 total of approximately 239,255,000 kg CO2e, primarily from purchased goods and services (about 113,190,000 kg CO2e). In the UK, Scope 1 emissions for 2024 were reported at approximately 2,702,000 kg CO2e. Convatec has set ambitious climate commitments, aiming for net zero emissions by 2045. The company has also committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 70% by 2030, using 2021 as the base year. Additionally, it targets a 52% reduction in Scope 3 emissions related to purchased goods and services, upstream transportation, and waste generated in operations per sold product within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and reflect Convatec's commitment to addressing climate change within the healthcare equipment and supplies sector. The company's strategic approach underscores its dedication to sustainability and reducing its carbon footprint across all scopes of emissions.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 4,001,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 26,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Convatec's Scope 3 emissions, which decreased by 3% last year and decreased by approximately 10% since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the primary emissions source at 47% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Convatec has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
